No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases
The results of the ECOG-ACRIN Cancer Research Group's phase three trial, E2810, are being orally presented at the 2019 annual ...
The results of the ECOG-ACRIN Cancer Research Group's phase three trial, E2810, are being orally presented at the 2019 annual ...
Findings from Arm H show that in a heavily pre-treated cohort of 17 distinct tumor types -- several rare -- ...
Olaparib doubled progression-free survival for patients with BRCA mutationsCredit: Robert Kozloff, UChicago Treatment with the drug olaparib significantly reduced the ...
Results from the phase III NRG Oncology clinical trial GOG 0261 comparing paclitaxel plus carboplatin (PC) to paclitaxel plus ifosfamide ...
Analyses of NRG Oncology/RTOG 9802 Suggests both IDH-mutant WHO-defined molecular subgroups of high-risk low-grade gliomas may benefit from the addition ...
Patients who received partial breast irradiation without chemotherapy experienced less fatigue, slightly poorer cosmesis on NRG Oncology trial Patient-reported outcome ...
Credit: Dana-Farber Cancer Institute After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with ...
NRG oncology trial shows tolerability of metformin for non-small cell lung cancer, no improvement in survival outcomes between treatments Initial ...
Initial experimental treatment arm results from NRG oncology trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe ...
Credit: University of Colorado Cancer Center University of Colorado Cancer Center led clinical trial data show that a predictive tool ...
The New Jersey Commission on Spinal Cord Research awarded a $598,000 grant to Nancy Chiaravalloti, Ph.D., of Kessler Foundation; the ...
In a new study published today in the Journal of Allergy and Clinical Immunology, scientists from King's College London have ...
Credit: University of Colorado Cancer Center Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK+ ...
Credit: University of Colorado Cancer Center Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.